8-K Announcements
6Material company update
May 4, 2026·SEC
Material company update
Apr 15, 2026·SEC
Material company update
Apr 3, 2026·SEC
Lisata Therapeutics, Inc.(LSTA)Earnings, Financials & Key Ratios
LSTA•NASDAQ
Price updated Jun 19, 2026
AboutLisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. The company was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. on September 15, 2022. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.Show more
- Revenue$170K-83.0%
- EBITDA-$18M+18.8%
- Net Income-$17M+17.0%
- EPS (Diluted)-1.91+20.4%
- Gross Margin14.12%-85.9%
- EBITDA Margin-10625.29%-377.9%
- Operating Margin-10711.18%-378.0%
- Net Margin-9756.47%-388.2%
- ROE-75.53%-45.9%
LSTA Key Insights
Lisata Therapeutics, Inc. (LSTA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Profits declining 15.3% over 5 years
- ✗Weak Piotroski F-Score: 1/9
- ✗Negative free cash flow
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when LSTA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
LSTA Price & Volume
Lisata Therapeutics, Inc. (LSTA) stock price & volume — 10-year historical chart
Loading chart...
LSTA Growth Metrics
Lisata Therapeutics, Inc. (LSTA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-38.65%
5 Years-
3 Years-
TTM-83%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM15.31%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM19.13%
Return on Capital
10 Years-63.42%
5 Years-60.83%
3 Years-61.76%
Last Year-82.65%
LSTA Recent Earnings
Lisata Therapeutics, Inc. (LSTA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (91%)●Beat Revenue 0/12 qtrs (0%)
Q2 2026Latest
May 11, 2026Metric
Actual
Est
EPS
$0.50
—
Rev
—
$94,351
Q2 2026
Mar 12, 2026Metric
Actual
Est
EPS
$0.33+35.3%
$0.51
Rev
$100,000+0.0%
$100,000
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.49+9.3%
$0.54
Rev
—
—
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.54+16.9%
$0.65
Rev
$70,000
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 11, 2026 | $0.50 | —vs $94,351 |
| Q2 2026 | Mar 12, 2026 | $0.33vs $0.51+35.3% | $100,000vs $100,000+0.0% |
| Q4 2025 | Nov 6, 2025 | $0.49vs $0.54+9.3% | — |
| Q3 2025 | Aug 7, 2025 | $0.54vs $0.65+16.9% | $70,000 |
Based on last 12 quarters of dataView full earnings history →
LSTA Peer Comparison
Lisata Therapeutics, Inc. (LSTA) competitors in Regenerative Medicine and Tissue Engineering — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ADCT | 138.64M | 1.09 | -0.97 | 14.85% | -173.02% | |||
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 TPVG | 202.99M | 5.00 | 4.10 | 36.55% | -19.55% | -3.39% | 1.33 | |
 CRVS | 1B | 11.91 | -22.47 | -38.92% | 0.02 | |||
 NKTR | 1.19B | 60.98 | -6.27 | -43.89% | -284.18% | -87% | 1.66 | |
 AGEN | 124.93M | 3.00 | -882.35 | 10.37% | 52.16% | |||
 FATE | 243.61M | 2.09 | -1.82 | -51.24% | -20.57% | -58.89% | 0.38 | |
 RCUS | 2.45B | 24.31 | -7.39 | -4.26% | -156.36% | -68.97% | 0.16 |
Compare LSTA vs Peers
Lisata Therapeutics, Inc. (LSTA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
LSTA Income Statement
Lisata Therapeutics, Inc. (LSTA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1M | 170K | 170K |
Revenue Growth % | -100% | - | - | - | - | - | - | - | -83% | -83% |
Cost of Goods Sold | 372K | 225K | 65K | 63K | 0 | 0 | 0 | 0 | 146K | 2K |
COGS % of Revenue | - | - | - | - | - | - | - | - | 85.88% | - |
Gross Profit | -372K▲ 0% | -225K▲ 39.5% | -65K▲ 71.1% | -63K▲ 3.1% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 1M▲ 0% | 24K▼ 97.6% | 168K▲ 0% |
Gross Margin % | - | - | - | - | - | - | - | 100% | 14.12% | 98.82% |
Gross Profit Growth % | -108.97% | 39.52% | 71.11% | 3.08% | 100% | - | - | - | -97.6% | - |
Operating Expenses | 27.59M | 16.99M | 20.09M | 19.14M | 29.05M | 57.6M | 25.71M | 23.41M | 18.23M | 17.47M |
OpEx % of Revenue | - | - | - | - | - | - | - | 2340.9% | 10725.29% | - |
Selling, General & Admin | 11.75M | 9.39M | 9.29M | 9.89M | 11.47M | 14.14M | 12.97M | 12.07M | 10.43M | 10.92M |
SG&A % of Revenue | - | - | - | - | - | - | - | 1207.5% | 6135.29% | - |
Research & Development | 17.14M | 7.59M | 13.5M | 9.25M | 17.58M | 43.46M | 12.73M | 11.33M | 7.95M | 6.55M |
R&D % of Revenue | - | - | - | - | - | - | - | 1133.4% | 4675.88% | - |
Other Operating Expenses | -1.3M | 824K | -2.7M | 0 | 0 | 0 | 0 | 0 | -146K | 0 |
Operating Income | -27.59M▲ 0% | -16.99M▲ 38.4% | -20.09M▼ 18.3% | -19.14M▲ 4.7% | -29.05M▼ 51.7% | -57.6M▼ 98.3% | -25.71M▲ 55.4% | -22.41M▲ 12.8% | -18.21M▲ 18.7% | -17.3M▲ 0% |
Operating Margin % | - | - | - | - | - | - | - | -2240.9% | -10711.18% | -10178.24% |
Operating Income Growth % | 11.94% | 38.44% | -18.28% | 4.71% | -51.74% | -98.28% | 55.37% | 12.83% | 18.74% | - |
EBITDA | -27.22M | -16.76M | -20.03M | -19.08M | -29M | -57.53M | -25.52M | -22.23M | -18.06M | -17.2M |
EBITDA Margin % | - | - | - | - | - | - | - | -2223.5% | -10625.29% | -10116.47% |
EBITDA Growth % | 11.87% | 38.42% | -19.48% | 4.72% | -51.95% | -98.42% | 55.64% | 12.87% | 18.76% | 19.95% |
D&A (Non-Cash Add-back) | 372K | 225K | 65K | 63K | 55K | 69K | 189K | 174K | 146K | 105K |
EBIT | -27.59M | -16.99M | -20.09M | -19.14M | -29.05M | -57.6M | -25.71M | -22.41M | -18.21M | -16.93M |
Net Interest Income | 0 | 0 | 740K | 132K | 151K | 1.05M | 2.72M | 1.88M | 806K | 336K |
Interest Income | 0 | 0 | 740K | 132K | 151K | 1.05M | 2.72M | 1.88M | 806K | 336K |
Interest Expense | 377.77K | 5K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | -105K | 819K | 740K | 132K | 76K | 897K | 2.54M | 1.63M | 661K | 565K |
Pretax Income | -27.7M▲ 0% | -16.17M▲ 41.6% | -19.35M▼ 19.7% | -19.01M▲ 1.8% | -28.97M▼ 52.4% | -56.7M▼ 95.7% | -23.17M▲ 59.1% | -20.78M▲ 10.3% | -17.55M▲ 15.6% | -16.74M▲ 0% |
Pretax Margin % | - | - | - | - | - | - | - | -2078.3% | -10322.35% | -9845.88% |
Income Tax | -11.53M | -1K | 0 | -10.87M | -1.51M | -2.48M | -2.33M | -798K | -962K | -387K |
Effective Tax Rate % | 41.62% | 0.01% | 0% | 57.18% | 5.2% | 4.37% | 10.06% | 3.84% | 5.48% | 2.31% |
Net Income | 22.98M▲ 0% | -16.17M▼ 170.4% | -20.1M▼ 24.3% | -8.15M▲ 59.5% | -27.47M▼ 237.0% | -54.23M▼ 97.4% | -20.84M▲ 61.6% | -19.98M▲ 4.1% | -16.59M▲ 17.0% | -16.35M▲ 0% |
Net Margin % | - | - | - | - | - | - | - | -1998.5% | -9756.47% | -9618.24% |
Net Income Growth % | 170.37% | -170.36% | -24.33% | 59.45% | -237.01% | -97.43% | 61.57% | 4.1% | 17.01% | 15.31% |
Net Income (Continuing) | -16.17M | -16.17M | -19.35M | -8.14M | -27.47M | -54.23M | -20.84M | -19.98M | -16.59M | -16.35M |
Discontinued Operations | 38.97M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | -318.28K | -272K | -263K | -254K | -254K | -254K | -254K | -254K | -254K | -254K |
EPS (Diluted) | 38.43▲ 0% | -25.03▼ 165.1% | -29.20▼ 16.7% | -7.91▲ 72.9% | -7.45▲ 5.8% | -10.47▼ 40.5% | -2.58▲ 75.4% | -2.40▲ 7.0% | -1.91▲ 20.4% | -1.82▲ 0% |
EPS Growth % | 151.37% | -165.13% | -16.66% | 72.91% | 5.82% | -40.54% | 75.36% | 6.98% | 20.42% | 19.13% |
EPS (Basic) | 38.43 | -25.03 | -29.20 | -7.91 | -7.45 | -10.47 | -2.58 | -2.40 | -1.91 | - |
Diluted Shares Outstanding | 597.93K | 645.93K | 688.33K | 1.03M | 3.69M | 5.18M | 8.07M | 8.33M | 8.69M | 9.01M |
Basic Shares Outstanding | 633.87K | 645.93K | 688.33K | 1.03M | 3.69M | 5.18M | 8.07M | 8.33M | 8.69M | 9.01M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
LSTA Balance Sheet
Lisata Therapeutics, Inc. (LSTA) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 61.11M | 44.11M | 25.97M | 35.33M | 96.18M | 71.88M | 53.92M | 34.58M | 17.7M | 14.02M |
Cash & Short-Term Investments | 55.08M | 43.05M | 25.16M | 34.57M | 94.97M | 69.23M | 50.53M | 31.25M | 15.96M | 13.06M |
Cash Only | 29.16M | 10.3M | 14.03M | 16.51M | 24.65M | 32.15M | 22.59M | 16.21M | 15.96M | 13.06M |
Short-Term Investments | 25.92M | 32.75M | 11.13M | 18.06M | 70.32M | 37.07M | 27.94M | 15.04M | 0 | 0 |
Accounts Receivable | 234.46K | 0 | 0 | 0 | 0 | 0 | 0 | 900K | 700K | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - | 328.5 | 1.5K | 1.29K |
Inventory | 5M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | 4.91K | - | - | - | - | - | - | - | - | - |
Other Current Assets | 4.77M | 0 | 0 | 0 | 0 | 2.65M | 3.39M | 2.43M | 1.05M | 960K |
Total Non-Current Assets | 2.27M | 474K | 1.18M | 671K | 826K | 1.16M | 770K | 424K | 41K | 39K |
Property, Plant & Equipment | 256.9K | 165K | 100K | 57K | 62K | 296K | 175K | 72K | 18K | 16K |
Fixed Asset Turnover | - | - | - | - | - | - | - | 13.89x | 9.44x | 6.54x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 334K | 263K | 192K | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 1.43M | 309K | 1.08M | 614K | 764K | 528K | 332K | 160K | 23K | 23K |
Total Assets | 63.38M▲ 0% | 44.58M▼ 29.7% | 27.15M▼ 39.1% | 36M▲ 32.6% | 97.01M▲ 169.5% | 73.03M▼ 24.7% | 54.69M▼ 25.1% | 35M▼ 36.0% | 17.74M▼ 49.3% | 14.06M▲ 0% |
Asset Turnover | - | - | - | - | - | - | - | 0.03x | 0.01x | 0.01x |
Asset Growth % | 22.27% | -29.66% | -39.09% | 32.59% | 169.45% | -24.71% | -25.11% | -36% | -49.31% | -184.73% |
Total Current Liabilities | 9.31M | 5.62M | 5.98M | 3.51M | 4.52M | 6.38M | 6.59M | 5.61M | 3.07M | 3.31M |
Accounts Payable | 1.34M | 762K | 1.49M | 1.02M | 1.93M | 2.65M | 2.42M | 1.28M | 1.02M | 510K |
Days Payables Outstanding | 1.32K | 1.24K | 8.37K | 5.91K | - | - | - | - | 2.55K | 133.68K |
Short-Term Debt | 159K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 4.68M | 3.1M | 0 | 0 | 0 | 0 | 0 | 0 | 2.05M | 2.81M |
Current Ratio | 6.56x | 7.85x | 4.35x | 10.08x | 21.27x | 11.26x | 8.18x | 6.16x | 5.76x | 4.23x |
Quick Ratio | 6.02x | 7.85x | 4.35x | 10.08x | 21.27x | 11.26x | 8.18x | 6.16x | 5.76x | 4.23x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | -132.39K |
Total Non-Current Liabilities | 3.87M | 1.51M | 624K | 254K | 485K | 327K | 210K | 72K | 72K | 72K |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 624K | 254K | 485K | 305K | 0 | 0 | 0 | 0 |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 3.87M | 1.51M | 0 | 0 | 0 | 22K | 210K | 72K | 72K | 72K |
Total Liabilities | 13.19M | 7.13M | 6.6M | 3.76M | 5.01M | 6.71M | 6.8M | 5.68M | 3.14M | 3.39M |
Total Debt | 159.18K | 0 | 978K | 624K | 714K | 485K | 168K | 137K | 0 | 0 |
Net Debt | -29M | -10.3M | -13.05M | -15.89M | -23.93M | -31.67M | -22.43M | -16.07M | -15.96M | -13.06M |
Debt / Equity | 0.00x | - | 0.05x | 0.02x | 0.01x | 0.01x | 0.00x | 0.00x | - | 0.00x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.00x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.76x |
Interest Coverage | -73.04x | -3397.40x | - | - | - | - | - | - | - | - |
Total Equity | 50.19M▲ 0% | 37.45M▼ 25.4% | 20.55M▼ 45.1% | 32.24M▲ 56.9% | 92M▲ 185.3% | 66.32M▼ 27.9% | 47.89M▼ 27.8% | 29.32M▼ 38.8% | 14.6M▼ 50.2% | 10.67M▲ 0% |
Equity Growth % | 1134.23% | -25.38% | -45.12% | 56.87% | 185.34% | -27.91% | -27.79% | -38.79% | -50.2% | -201.8% |
Book Value per Share | 83.94 | 57.98 | 29.86 | 31.33 | 24.95 | 12.80 | 5.93 | 3.52 | 1.68 | 1.18 |
Total Shareholders' Equity | 50.51M | 37.73M | 20.82M | 32.5M | 92.25M | 66.58M | 48.15M | 29.57M | 14.86M | 10.93M |
Common Stock | 9.48K | 10K | 11K | 19K | 4K | 8K | 8K | 8K | 9K | 9K |
Retained Earnings | -381.81M | -397.98M | -417.4M | -425.55M | -453.02M | -507.24M | -528.08M | -548.07M | -564.65M | -569.14M |
Treasury Stock | -708K | -708K | -708K | -708K | -708K | -708K | -708K | -708K | -708K | 0 |
Accumulated OCI | -27.98K | -32K | 2K | -13K | -70K | -29K | -42K | -81K | -37K | -21K |
Minority Interest | -318.28K | -272K | -263K | -254K | -254K | -254K | -254K | -254K | -254K | -254K |
LSTA Cash Flow Statement
Lisata Therapeutics, Inc. (LSTA) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -20.88M | -19.99M | -18.88M | -8.82M | -22.25M | -21.17M | -20.03M | -19.36M | -15.95M | -13.63M |
Operating CF Margin % | - | - | - | - | - | - | - | -1935.6% | -9381.76% | - |
Operating CF Growth % | 11.8% | 4.26% | 5.52% | 53.27% | -152.13% | 4.83% | 5.38% | 3.37% | 17.6% | 63.57% |
Net Income | -16.17M | -16.17M | -19.35M | -8.14M | -27.47M | -54.23M | -20.84M | -19.98M | -16.59M | -16.35M |
Depreciation & Amortization | 372K | 225K | 65K | 63K | 55K | 69K | 189K | 174K | 146K | 105K |
Stock-Based Compensation | 1.96M | 2.45M | 1.29M | 1.26M | 2M | 2.64M | 2.04M | 1.65M | 1.23M | 696K |
Deferred Taxes | -12.1M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | -86.29K | -1.15M | 232K | 307K | 2.51M | 31.18M | -957K | -325K | 552K | 957K |
Working Capital Changes | 5.15M | -5.35M | -1.12M | -2.32M | 647K | -831K | -462K | -873K | -1.29M | 963K |
Change in Receivables | -95.69K | 0 | 0 | 0 | 0 | 0 | 0 | -900K | 401K | 251K |
Change in Inventory | -571.61K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 5.67M | -5.9M | -1.86M | -2.84M | 1.25M | -223K | 88K | -995K | -2.57M | -528K |
Cash from Investing | 41.27M | -4.71M | 21.43M | -7.28M | -54.9M | 28.91M | 10.1M | 13.23M | 15.09M | 5.66M |
Capital Expenditures | -135.28K | -134K | 0 | -20K | -60K | -285K | 0 | 0 | -28K | -28K |
CapEx % of Revenue | - | - | - | - | - | - | - | - | 16.47% | 16.47% |
Acquisitions | 67.88M | 2.55M | 0 | 7.26K | 54.84K | -3.32M | 0 | -130K | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -188.79K | 2.55M | 0 | -7.26K | -54.84K | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | -931.77K | 824K | 1.18M | 18.58M | 85.28M | -224K | 385K | -206K | 599K | 803K |
Debt Issued (Net) | -6.21M | -159K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 5.7M | 1.03M | 1.31M | 18.73M | 85.5M | 43K | 321K | 68K | 852K | 972K |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | -419K | -48K | -130K | -148K | -224K | -267K | 64K | -274K | -253K | -169K |
Net Change in Cash | 19.46M▲ 0% | -23.87M▼ 222.6% | 3.73M▲ 115.6% | 2.48M▼ 33.6% | 8.13M▲ 228.0% | 7.51M▼ 7.7% | -9.56M▼ 227.4% | -6.38M▲ 33.2% | -253K▲ 96.0% | -7.16M▲ 0% |
Free Cash Flow | -21.01M▲ 0% | -20.12M▲ 4.2% | -18.88M▲ 6.2% | -8.84M▲ 53.2% | -22.3M▼ 152.2% | -21.45M▲ 3.8% | -20.03M▲ 6.6% | -19.36M▲ 3.4% | -15.98M▲ 17.5% | -13.66M▲ 0% |
FCF Margin % | - | - | - | - | - | - | - | -1935.6% | -9398.24% | -8034.12% |
FCF Growth % | 20.76% | 4.24% | 6.15% | 53.17% | -152.23% | 3.81% | 6.63% | 3.37% | 17.46% | 23.09% |
FCF per Share | -35.14 | -31.15 | -27.43 | -8.59 | -6.05 | -4.14 | -2.48 | -2.32 | -1.84 | -1.52 |
FCF Conversion (FCF/Net Income) | -0.91x | 1.24x | 0.94x | 1.08x | 0.81x | 0.39x | 0.96x | 0.97x | 0.96x | 0.84x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
LSTA Key Ratios
Lisata Therapeutics, Inc. (LSTA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 84.71% | -36.89% | -69.31% | -30.87% | -44.21% | -68.5% | -36.49% | -51.77% | -75.53% | -103.54% |
Return on Invested Capital (ROIC) | -238.72% | -52.71% | -86.97% | -120.39% | -51.62% | -84.11% | -64.14% | -86.83% | -229.72% | 3174.86% |
Gross Margin | - | - | - | - | - | - | - | 100% | 14.12% | 98.82% |
Net Margin | - | - | - | - | - | - | - | -1998.5% | -9756.47% | -9618.24% |
Debt / Equity | 0.00x | - | 0.05x | 0.02x | 0.01x | 0.01x | 0.00x | 0.00x | - | 0.00x |
Interest Coverage | -73.04x | -3397.40x | - | - | - | - | - | - | - | - |
FCF Conversion | -0.91x | 1.24x | 0.94x | 1.08x | 0.81x | 0.39x | 0.96x | 0.97x | 0.96x | 0.84x |
Revenue Growth | -100% | - | - | - | - | - | - | - | -83% | -83% |
Related:LSTA Dividend History·LSTA Revenue History·LSTA Price History·LSTA P/E History·LSTA Financial Ratios·LSTA Institutional Holders
LSTA SEC Filings & Documents
Lisata Therapeutics, Inc. (LSTA) SEC filings — annual & quarterly reports (10-K, 10-Q)
LSTA Frequently Asked Questions
Lisata Therapeutics, Inc. (LSTA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Lisata Therapeutics, Inc. (LSTA) reported $0.2M in revenue for fiscal year 2025. This represents a 99% decrease from $21.1M in 1995.
Lisata Therapeutics, Inc. (LSTA) saw revenue decline by 83.0% over the past year.
Lisata Therapeutics, Inc. (LSTA) reported a net loss of $16.4M for fiscal year 2025.
Dividend & Returns
Lisata Therapeutics, Inc. (LSTA) has a return on equity (ROE) of -75.5%. Negative ROE indicates the company is unprofitable.
Lisata Therapeutics, Inc. (LSTA) had negative free cash flow of $13.7M in fiscal year 2025, likely due to heavy capital investments.